Navoximod

Drug Profile

Navoximod

Alternative Names: GDC-0919; NLG-919; RG-6078

Latest Information Update: 11 Jul 2017

Price : $50

At a glance

  • Originator Lankenau Institute for Medical Research
  • Developer Chugai Pharmaceutical; Genentech; NewLink Genetics Corporation
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Immunomodulators; Indoleamine-pyrrole 2,3-dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 08 Jun 2017 Genentech plans to terminate the license for navoximod
  • 04 Jun 2017 Interim adverse events, pharmacokinetics, pharmacodynamics and efficacy data from a phase Ib trial in Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 01 Jun 2016 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease) in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top